Oric Pharmaceuticals CFO Executes 10b5-1 Sale after Option Exercise
Rhea-AI Filing Summary
Oric Pharmaceuticals insider transactions by CFO Dominic Piscitelli show a simultaneous option exercise and sale on 10/06/2025. The filing reports exercise of 11,000 stock options at an exercise price of $4.36 per share, resulting in immediate acquisition of 11,000 common shares. Those 11,000 shares were sold under a Rule 10b5-1 plan at a weighted average price of $14.5199 per share, completing sales in the $14.50–$14.53 range and leaving the reporting person with 48,317 shares outstanding directly. After the transactions, the reporting person holds 196,500 shares subject to outstanding options. The sale was executed pursuant to a trading plan adopted on 06/24/2025.
Positive
- Use of a Rule 10b5-1 trading plan adopted on 06/24/2025 provides procedural defensibility for the sales
- Realized proceeds per share were materially above exercise price: sold at a weighted average of $14.5199 vs exercise at $4.36
Negative
- Net direct holdings decreased from 59,317 to 48,317 shares after the sale
- Significant remaining option exposure of 196,500 shares outstanding could lead to future dilution if exercised
Insights
Simultaneous option exercise and planned sale shows routine liquidity event, not a disclosed judgment on value.
The reporting person exercised 11,000 stock options at an exercise price of $4.36 and sold those same shares under a Rule 10b5-1 plan for a weighted average of $14.5199. This sequence converted vested option value to cash while retaining direct ownership of 48,317 shares and holding options for 196,500 underlying shares.
Risks include potential market perception when an officer sells shares; however, the existence of a pre-established 10b5-1 plan (adopted 06/24/2025) reduces concerns about opportunistic timing. Monitor future Form 4 filings for additional sales or exercises and any amendments to trading plans within the next 12 months.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) | 11,000 | $0.00 | -- |
| Exercise | Common Stock | 11,000 | $4.36 | $48K |
| Sale | Common Stock | 11,000 | $14.5199 | $160K |
Footnotes (1)
- The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 24, 2025. Represents the weighted average share price of an aggregate total of 11,000 shares sold in the price range of $14.50 to $14.53 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
